Page 73 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 3. Eligibility criteria for enrollment in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Term used in Age Gleason score # biopsy PSA Imaging Stage Behavioral indication (other
[Pubmed ID] original article (yr) cores /% (ng/mL) than patients’ choice or
Enrollment years cores preference)
Memorial Sloan- AS – No Gleason ≤3 positive <10 – T1-T2a –
Kettering Cancer grade 4 or 5 biopsy cores
Center, US 115 (minimum 10), no
[21167529] biopsy core
containing >50%
1997-2009 cancer
involvement
ProtecT, UK 116 Active – – – – – “Clinically –
[19603015] monitoring localized
prostate
2000-2008 cancer”
Dana-Farber AS – ≤6 with no <3 cores positive – – T1c-T2c –
Cancer Institute, pattern 4 for cancer and <
US 117 50% of cancer in
[21167525] any core

2000-2010
Kagawa Medical AS 50-80 ≤6 TRUS-guided six ≤20 – T1cN0M0 –
Univ., Japan 118 sextant biopsy
[18272471]
1-2 positive cores
2002-2003 per 6-12
systematic biopsy
cores
Cleveland clinic, Surveillance – No primary or – ≤10 (part of D’Amico – Clinical stage –
US 119 secondary criteria) T2a or fewer
[21256549] Gleason (part of D’Amico
scores 4 or 5 criteria)
2004-2009
PRIAS, AS – ≤3+3=6 TRUS guided ≤10 – T1c or T2 –
d
Netherlands 120 biopsy
[19817747] PSA density ≤ 0.2
Adequate biopsy ng/ml/ml
2006 – ongoing sampling
according to
biopsy protocol;
maximal 2 biopsy
cores invaded
with prostate
cancer

36